Francisco Sanchez-Vega

Assistant Attending Computational Biologist

Memorial Sloan Kettering Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (39)

Year:

2025

Chromosomal instability (CIN) generates aneuploid genomes that are characteristic of most cancers. While bulk genome sequencing reveals historical CIN, it lacks the resolution to identify ongoing CIN that actively shapes genome evolution. Here, we present a computational framework that leverages single-cell whole-genome sequencing (scWGS) to identify and quantify ongoing CIN by detecting cell-unique copy number alterations and probabilistically mapping them to known CIN signatures. We validated this framework generating in vitro models with four types of induced CIN, correctly identifying the induced-CIN type in each case. When applied to cell lines and organoids with ongoing homologous recombination deficiency, our method showed improved identification of sensitivity to PARP inhibition and platinum-based chemotherapy. Analysing scWGS data from 8 triple-negative breast cancers, we linked ongoing impaired non-homologous end joining to subclonal diversification, a finding further supported in cohorts of 179 unmatched primary and metastatic TNBCs and 39 matched cases. Collectively, our results demonstrate that distinguishing ongoing from historical chromosomal instability uncovers a distinct dimension of tumour evolution, suggesting that effective precision oncology will require integrating measurements of both past genomic scars and active mutational processes.

Year:

2025

Cohort overview and description of clinical features. A, CONSORT diagram of patients included in the study. RT, radiotherapy. B, Baseline comorbidities by racial and ethnic groups. C, Description of the type of operative approach by racial group and procedure year. Left top plot, percentage of racial groups included in the study by procedure year; left bottom plot, ratio of the approach by procedure year. D, Differences in receipt of GCC by racial groups. Results are shown for NHW (left), NHB (middle), and Hispanic (right) patients.

Year:

2025

In this study, we examined racial disparities in guideline-concordant care (GCC) and clinical outcomes of patients with colon cancer treated at a single comprehensive cancer center. We analyzed data from self-reported Hispanic, non-Hispanic Black (NHB), and non-Hispanic White (NHW) patients who underwent curative colectomy for stage I to III colon cancer between 2006 and 2021 at Memorial Sloan Kettering Cancer Center. GCC was defined as retrieval of ≥12 lymph nodes and appropriate receipt of adjuvant chemotherapy. Recurrence and overall survival from the time of surgery were compared using the Kaplan–Meier method and the log-rank test. Multivariable analyses were performed using Cox regression. The study included 2,209 patients, with 1,911 NHW, 153 NHB, and 145 Hispanic patients. NHW patients were older, whereas NHB patients had higher percentages of Medicaid coverage, obesity, and lower socioeconomic status. NHB patients more often presented with stage III disease and underwent open surgery. Receipt of GCC was not different by race. NHB patients had the highest 5-year recurrence rate compared with NHW and Hispanic patients (27% vs. 15.7% vs. 15.1%; P = 0.03). NHB race (HR = 1.43; P = 0.07) and low body mass index (HR = 1.98; P = 0.05) were associated with an increased risk of recurrence with marginal significance. NHB race was associated with an increased risk of recurrence in stage I disease (HR = 3.52; P = 0.03). NHB patients had shorter recurrence-free survival, despite standardized quality of care. NHB race was independently associated with an increased risk of recurrence in stage I disease. Significance: This study compares receipt of GCC, disease recurrence, and survival among White, Black, and Hispanic patients with nonmetastatic colon cancer treated at a single comprehensive cancer center with standardized quality of care and comparable access to health care. Black patients had higher rates of recurrence in this study.

Year:

2025

Programmed death-ligand 1 (PD-L1) IHC is the most commonly used biomarker for immunotherapy response. However, quantification of PD-L1 status in pathology slides is challenging. Neither manual quantification nor a computer-based mimicking of manual readouts is perfectly reproducible, and the predictive performance of both approaches regarding immunotherapy response is limited. In this study, we developed a deep learning (DL) method to predict PD-L1 status directly from raw IHC image data, without explicit intermediary steps such as cell detection or pigment quantification. We trained the weakly supervised model on PD-L1–stained slides from the non–small cell lung cancer (NSCLC)-Memorial Sloan Kettering (MSK) cohort (N = 233) and validated it on the pan-cancer-Vall d'Hebron Institute of Oncology (VHIO) cohort (N = 108). We also investigated the performance of the model to predict response to immune checkpoint inhibitors (ICI) in terms of progression-free survival. In the pan-cancer-VHIO cohort, the performance was compared with tumor proportion score (TPS) and combined positive score (CPS). The DL model showed good performance in predicting PD-L1 expression (TPS ≥ 1%) in both NSCLC-MSK and pan-cancer-VHIO cohort (AUC 0.88 ± 0.06 and 0.80 ± 0.03, respectively). The predicted PD-L1 status showed an improved association with response to ICIs [HR: 1.5 (95% confidence interval: 1–2.3), P = 0.049] compared with TPS [HR: 1.4 (0.96–2.2), P = 0.082] and CPS [HR: 1.2 (0.79–1.9), P = 0.386]. Notably, our explainability analysis showed that the model does not just look at the amount of brown pigment in the IHC slides, but also considers morphologic factors such as lymphocyte conglomerates. Overall, end-to-end weakly supervised DL shows potential for improving patient stratification for cancer immunotherapy by analyzing PD-L1 IHC, holistically integrating morphology and PD-L1 staining intensity. Significance: The weakly supervised DL model to predict PD-L1 status from raw IHC data, integrating tumor staining intensity and morphology, enables enhanced patient stratification in cancer immunotherapy compared with traditional pathologist assessment.

Year:

2024

Year:

2024

Background: Abdominoperineal resection (APR) has been advocated for persistent or recurrent disease after failure of chemoradiation (CRT) for anal squamous cell cancer (SCC). Treatment with salvage APR can potentially achieve a cure. This study aimed to analyze oncological outcomes for salvage APR in a recent time period at a comprehensive cancer center. Methods: A retrospective review of all patients who underwent APR for biopsy-proven persistent or recurrent anal SCC between 1 January 2007 and 31 December 2020 was performed. Patients with stage IV disease at the time of initial diagnosis and patients with missing data were excluded. Univariate analysis was used with a chi-square test for categorical variables, and non-parametric tests were used for continuous variables. Kaplan–Meier survival analysis was performed to evaluate disease-specific (DSS), post-APR local recurrence-free (RFS), and disease-free survival (DFS). Results: A total of 96 patients were included in the analysis: 39 (41%) with persistent disease and 57 (59%) with recurrent SCC after chemoradiation had been completed. The median follow-up was 22 months (IQR 11–47). Forty-nine patients (51%) underwent extended APR and/or pelvic exenteration. Eight (8%) patients developed local recurrence, 30 (31%) developed local and distant recurrences, and 16 (17%) developed distant recurrences alone. The 3-year DSS, post-APR local recurrence-free survival, and disease-free survival were 53.8% (95% CI 43.5–66.5%), 54.5% (95% CI 44.4–66.8%), and 26.8% (95% CI 18.6–38.7%), respectively. In multivariate logistic regression analysis, positive microscopic margin (OR 10.0, 95% CI 2.16–46.12, p = 0.003), positive nodes in the surgical specimen (OR 9.19, 95% CI 1.99–42.52, p = 0.005), and lymphovascular invasion (OR 2.61 95% CI 1.05–6.51, p = 0.04) were associated with recurrence of disease. Gender, indication for APR (recurrent vs. persistent disease), HIV status, extent of surgery, or type of reconstruction did not influence survival outcomes. Twenty patients had targeted tumor-sequencing data available. Nine patients had PIK3CA mutations, seven of whom experienced a recurrence. Conclusions: Salvage APR for anal SCC after failed CRT was associated with poor disease-specific survival and low recurrence-free survival. Anal SCC patients undergoing salvage APR should be counseled that microscopic positive margins, positive lymph nodes, or the presence of lymphovascular invasion in the APR specimen are prognosticators for disease relapse. Our results accentuate the necessity for additional treatment strategies for the ongoing treatment challenge of persistent or recurrent anal SCC after failed CRT.

Year:

2024

Year:

2024

(1) Background: Adenosquamous carcinoma (ASC) is a rare subtype of colon cancer. Its rarity makes characterization challenging, although colonic ASC is believed to present at more advanced stages and have worse outcomes versus adenocarcinoma. This study aims to characterize the clinicopathological characteristics and clinical outcomes of colonic ASC. (2) Methods: This is a single-center, retrospective review of patients diagnosed with colonic ASC from 2000 to 2020. Data extracted included patient demographics, staging at diagnosis, tumor clinicopathologic and genetic characteristics, and clinical outcomes. (3) Results: Among 61,126 patients with colorectal cancer, 13 (0.02%) had colonic ASC, with a mean age at diagnosis of 48.7 years. The cecum/ascending colon was the most common primary site (6/13, 46.2%), and all except one patient was diagnosed with Stage III or IV disease. Among the eight patients with mismatch repair genetics available, only one was mismatch repair deficient. Eleven patients (84.6%) underwent surgery, and 11 likewise received some form of chemotherapy. Recurrence occurred in 7 of 13 patients (53.8%), and the overall five-year survival rate was 38.5%. The median survival rate was 39.4 months overall (30.5 months for Stage III, 23.7 months for Stage IV). (4) Conclusions: Overall, colonic ASC is rare, and this cohort of colonic ASC patients demonstrated advanced stage at diagnosis, frequent recurrence, and poor overall survival. Additional research remains to compare these characteristics with those of comparably staged adenocarcinoma and to develop specific management recommendations.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (42)

Naoto Ueno

Professor of Medicine

University of Hawai'i Cancer Center

UNITED STATES
View details

Paul Romesser

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Elizabeth Christie

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Wendy Rathmell

Professor, Department Chair

Vanderbilt University Medical Center

UNITED STATES
View details

Lara Urban

Principal Investigator

Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit

GERMANY
View details

Baby Satravada

Bioinfo.Software Engr I

Sloan Kettering Institute

UNITED STATES
View details

Raquel Perez-Lopez

Vall d'Hebron Institut de Recerca

SPAIN
View details

Hannah Thompson

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Jihoon Kim

Assistant Professor

Yale University

UNITED STATES
View details

Jesse Joshua Smith

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sohrab Shah

Professor

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Julio Garcia-Aguilar

Chief Attending Surgeon, Colorectal Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Geoff Macintyre

Group leader

Centro Nacional de Investigaciones Oncológicas

SPAIN
View details

Rory Johnson

University College Dublin – National University of Ireland, Dublin

IRELAND
View details

Daniel Brewer

Professor of Medical Bioinformatics and Genomics

University of East Anglia

UNITED KINGDOM
View details

Peter Stetson

Chief Health Informatics Officer, Deputy Physician-in-Chief

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Abel Gonzalez-Perez

Co-PI

IRB Barcelona

SPAIN
View details

Jakob Nikolas Kather

Chair of Clinical Artificial Intelligence

TU Dresden

GERMANY
View details

Carlos Caldas

Professor

Hebrew University of Jerusalem

ISRAEL
View details

Seong Gu Heo

Dana-Farber Cancer Institute

UNITED STATES
View details

Steven Maron

Assistant Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Joshua Stuart

Department Chair

University of California, Santa Cruz

UNITED STATES
View details

Nigel Jamieson

University of Glasgow

UNITED KINGDOM
View details

Francisco G Rodriguez Gonzalez

Københavns Universitet

DENMARK
View details

Elena Garralda

Director

-

SPAIN
View details

Carmen Guerra

"Científico Titular " (On leave of absence)

CSIC

SPAIN
View details

Maxime Tarabichi

Group Leader

Université libre de Bruxelles

BELGIUM
View details

Alicia L Bruzos

Junior Group Leader of Marine Transmissible Cancers Group

Max Planck Institute for Marine Microbiology

GERMANY
View details

Paolo Nuciforo

Head

Vall d´Hebron Institut d´Oncologia

SPAIN
View details

Rami Vanguri

Assistant Professor

University of Pittsburgh

UNITED STATES
View details

Marc Gollub

Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

qiang pan-hammarstrom

Professor, head of the Immunology Division

Karolinska University Hospital

SWEDEN
View details

Isidro Cortes Ciriano

Research Group Leader

European Bioinformatics Institute

UNITED KINGDOM
View details

Matthew Fittall

Honorary Associate Professor

University College London

UNITED KINGDOM
View details

Jan Komorowski

Senior Professor of Bioinformatics

Uppsala University

SWEDEN
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Samantha Bersani

University of Verona

ITALY
View details

Anke Katharina Bergmann

Director, Chair

University Hospital Würzburg

GERMANY
View details

Zsofia Kote-Jarai

Senior Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Rodrigo Toledo

Miguel Servet Researcher (Assistant Professor)

Vall d'Hebron Institute of Oncology

SPAIN
View details

Young Seok Ju

Associate Professor

Korea Advanced Institute of Science and Technology

SOUTH KOREA
View details